Aurobindo Pharma’s wholly owned subsidiary-- Aurobindo Pharma USA Inc., has entered into a Collaboration and License Agreement on November 22, 2024 with a global pharma major for development of specific products across respiratory therapeutic area and their commercialisation.

Both the parties will co-exclusively commercialize the product. The products, once commercialized, will be manufactured at Partner’s facility and will be marketed by both the parties. Aurobindo has an option to technology transfer at a future date. A cost-sharing arrangement has been agreed by both the parties with each of them contributing 50% of the cost incurred with an overall cap of $90 million for Aurobindo over the development period. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.